Hemlibra threatens to take market share from Advate
Takeda aiming for $1.4bn savings per year
Express Scripts’ Miller backs “responsible” price
CEO wants “broad nerve block label” for Exparel
But deal with Samsung prevents US launch until mid-2023
Focus on services, not products, report argues.
GSK is left as sole bidder amid speculation that the sale is off.
Mundipharma’s third biosimilar tie-up with Celltrion
Proposals also include fresh attack on drug prices
AstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early-stage inflammation and autoimmunity programmes.
Lantern Pharma, a pharma company which uses artificial intelligence to develop shelved oncology drugs has joined Genomics England’s groundbreaking industry partnership.
Tesaro is to combine its PARP-inhibitor drug Zejula with Roche’s PD-L1 immunotherapy Tecentriq in clinical trials for metastatic bladder cancer.
New phase 3b trial results show Lilly’s Trulicity combined with an SGLT2 inhibitor failed to show any benefits above and beyond Trulicity’s blood glucose lowering.
NICE says no to Halaven in second line breast cancer
Doubts over nerve blocker Exparel